Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of SHR-9839 plus antitumor therapy in patients with solid tumors
CTR20254318Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-9839 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Feb 2026; status: active.
02
Drugs
SHR-9839
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254318.